tradingkey.logo

Gilead Sciences Inc

GILD
View Detailed Chart

113.663USD

-1.097-0.96%
Market hours ETQuotes delayed by 15 min
141.51BMarket Cap
23.72P/E TTM

Gilead Sciences Inc

113.663

-1.097-0.96%
Intraday
1m
30m
1h
D
W
M
D

Today

-0.96%

5 Days

+0.09%

1 Month

+2.52%

6 Months

+17.24%

Year to Date

+23.05%

1 Year

+45.63%

View Detailed Chart

Agency Rating

Analyst Rating

Based on 30 analysts
BUY
Current Rating
118.308
Target Price
3.57%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

172
Total
5
Median
8
Average
Company name
Ratings
Analysts
Gilead Sciences Inc
GILD
30
Biogen Inc
BIIB
37
Vertex Pharmaceuticals Inc
VRTX
34
Alnylam Pharmaceuticals Inc
ALNY
33
Amgen Inc
AMGN
33
Sarepta Therapeutics Inc
SRPT
27
1
2
3
...
35

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Buy
Sell(2)
Neutral(2)
Buy(9)
Indicators
Sell(1)
Neutral(2)
Buy(4)
Indicators
Value
Direction
MACD(12,26,9)
0.750
Buy
RSI(14)
58.242
Neutral
STOCH(KDJ)(9,3,3)
68.677
Neutral
ATR(14)
2.835
Low Volatility
CCI(14)
102.520
Buy
Williams %R
28.832
Buy
TRIX(12,20)
0.122
Sell
StochRSI(14)
39.701
Buy
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
114.284
Sell
MA10
112.045
Buy
MA20
111.748
Buy
MA50
110.219
Buy
MA100
108.347
Buy
MA200
101.526
Buy

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Anitocabtagene autoleucel, Sacituzumab govitecan-hziy, and Domvanalimab and zimberelimab. Biktarvy is an oral formulation dosed once a day for the treatment of HIV-1 infection in certain patients. It operates in more than 35 countries worldwide.
Ticker SymbolGILD
CompanyGilead Sciences Inc
CEOMr. Daniel P. O'Day
Websitehttps://www.gilead.com/
KeyAI